PROGNOSTIC SIGNIFICANCE OF EXPRESSION OF CD44 VARIANTS IN HEAD AND NECK CANCER

CD44 变异体在头颈癌中表达的预后意义

• 批准号: 09671757
• 负责人: FUJII Masato
• 金额: $ 1.92万
• 依托单位: KEIO UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09671757/
• 关键词: HEAD AND NECK CANCER; CELL ADHESION MOLECULE; CD44

Splice variants of the cell surface glycoprotein CD44(CD44v)have been reported to be involved in the progression of various human tumors. The aim of this study is to determine the correlation between the expression of CD44 isoforms and the clinicopathological features of head and neck squamous cell carcinomas(HNSCCs). The expression of CD44v was evaluated immunohistochemically in paraffin-embedded tissues from 89 primary lesions, using monoclonal antibodies against CD44 standard(CD44st), variant 6(v6)and variant 2(v2).Cancer tissues from 89(100%), 85(95.5%)and 59(66.3%)patients showed positive immunoreactivity for CD44st, v6 and v2, respectively. Significant correlations were observed between the down-regulation of v6 or v2 and poorer differentiation of the tumor cells(p=0.01 and 0.02, respectively). As for lymph node status, down-regulation of v6 but not v2 was correlated significantly with increased rate of metastasis to the cervical lymph nodes(p=0.02).Down-regulation of v2 expression was correlated with shorter disease free survival(p=0.01), but no such correlation with v6 was seen in these tumors(p=0.46). We could not find any significant correlation between expression of v2 or v6 and T stage. Cox's multivariate analysis revealed that only v2 expression and lymph node status were independent prognostic factors.These findings suggest that down-regulation of expression of CD44v(v6 and v2)may be one of the biological markers for the degree of malignancy in HNSCCs.

据报道，细胞表面糖蛋白 CD44 (CD44v) 的剪接变体参与多种人类肿瘤的进展。本研究的目的是确定CD44亚型的表达与头颈鳞状细胞癌（HNSCC）临床病理特征之间的相关性。使用针对CD44标准品（CD44st）、变体6（v6）和变体2（v2）的单克隆抗体，对89个原发灶的石蜡包埋组织中CD44v的表达进行免疫组织化学评估。来自89（100％）、85（95.5％）和59（66.3％）患者的癌症组织显示出阳性免疫反应性 分别为 CD44st、v6 和 v2。 v6或v2的下调与肿瘤细胞分化较差之间观察到显着相关性（分别p=0.01和0.02）。至于淋巴结状态，v6表达下调而非v2表达与颈部淋巴结转移率增加显着相关（p=0.02）。v2表达下调与较短的无病生存期相关（p=0.01），但在这些肿瘤中未发现与v6存在这种相关性（p=0.46）。我们没有发现v2或v6的表达与T期之间存在任何显着相关性。 Cox的多变量分析显示，只有v2表达和淋巴结状态是独立的预后因素。这些结果表明CD44v（v6和v2）表达的下调可能是HNSCC恶性程度的生物学标志之一。

项目成果

菅家 稔: "頭頸部扁平上皮癌におけるCD44 variant発現の臨床病理学的意義"日本癌学会総会記事. 89. 497-497 (1998)

Minoru Sugaya：“头颈鳞状细胞癌中 CD44 变异表达的临床病理学意义”日本癌症协会大会文章 89. 497-497 (1998)。

Masato Fujii: "The expression of CD44 V6_2V2 in head and neck cancer" Head and Neck. 20. 453-453 (1998)

Masato Fujii：“CD44 V6_2V2 在头颈癌中的表达”Head and Neck。

Minoru Kanke, et al.: "Role of CD44 Variant Exon 6 in Invasion of Head and Neck Squamous Cell Carcinoma"Arch Otolaryngol Head and Neck Surg. 126. 1217-1223 (2000)

Minoru Kanke 等人：“CD44 变异体外显子 6 在头颈鳞状细胞癌侵袭中的作用”Arch Otolaryngol Head and Neck Surg。

菅家 稔: "頭頸部偏平上皮癌におけるCD44変異体発現の免疫組織学的検討" 日本癌学会総会記事. 416-416 (1997)

Minoru Sugaya：“头颈鳞状细胞癌中CD44突变体表达的免疫组织学研究”日本癌症协会大会文章416-416（1997）。

Masato Fujii, Yutaka Tokumaru, Yorihisa Imanishi, Minoru Kanke, Toshiki Tomita, Jin Kanzaki, Yasuhiro Mtsumura: "The expression of CD44v6, v2 in head and neck cancer"Head and Neck. 20. 453-453 (1998)

Masato Fujii、Yutaka Tokumaru、Yorihisa Imanishi、Minoru Kanke、Toshiki Tomita、Jin Kanzaki、Yasuhiro Mtsumura：“头颈癌中 CD44v6、v2 的表达”Head and Neck。